NASDAQ:BYSI

BeyondSpring Stock Forecast, Price & News

$15.15
-0.67 (-4.24 %)
(As of 09/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.06
$16.32
50-Day Range
$9.26
$31.31
52-Week Range
$8.90
$33.00
Volume1.32 million shs
Average Volume1.33 million shs
Market Capitalization$592.46 million
P/E RatioN/A
Dividend YieldN/A
Beta0.87
30 days | 90 days | 365 days | Advanced Chart
Receive BYSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BeyondSpring and its competitors with MarketBeat's FREE daily newsletter.


BeyondSpring logo

About BeyondSpring

BeyondSpring, Inc. engages in the the development and commercialization of immuno-oncology cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. It operates through PRC and U.S. geographical segments. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.73 out of 5 stars

Medical Sector

846th out of 1,352 stocks

Pharmaceutical Preparations Industry

415th out of 665 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











BeyondSpring (NASDAQ:BYSI) Frequently Asked Questions

Is BeyondSpring a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BeyondSpring in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BeyondSpring stock.
View analyst ratings for BeyondSpring
or view top-rated stocks.

What stocks does MarketBeat like better than BeyondSpring?

Wall Street analysts have given BeyondSpring a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BeyondSpring wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting BeyondSpring?

BeyondSpring saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 2,230,000 shares, an increase of 23.9% from the August 15th total of 1,800,000 shares. Based on an average daily volume of 3,090,000 shares, the short-interest ratio is currently 0.7 days. Currently, 10.9% of the company's stock are sold short.
View BeyondSpring's Short Interest
.

When is BeyondSpring's next earnings date?

BeyondSpring is scheduled to release its next quarterly earnings announcement on Tuesday, November 16th 2021.
View our earnings forecast for BeyondSpring
.

How were BeyondSpring's earnings last quarter?

BeyondSpring Inc. (NASDAQ:BYSI) announced its quarterly earnings results on Thursday, September, 9th. The company reported ($0.49) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.49). During the same quarter in the previous year, the company posted ($0.46) EPS.
View BeyondSpring's earnings history
.

How has BeyondSpring's stock price been impacted by Coronavirus (COVID-19)?

BeyondSpring's stock was trading at $11.35 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BYSI stock has increased by 33.5% and is now trading at $15.15.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for BYSI?

5 equities research analysts have issued twelve-month price targets for BeyondSpring's stock. Their forecasts range from $25.00 to $95.00. On average, they expect BeyondSpring's stock price to reach $58.75 in the next twelve months. This suggests a possible upside of 287.8% from the stock's current price.
View analysts' price targets for BeyondSpring
or view top-rated stocks among Wall Street analysts.

Who are BeyondSpring's key executives?

BeyondSpring's management team includes the following people:
  • Lan Huang, Chairman & Chief Executive Officer
  • Richard J. Daly, Chief Operating Officer
  • Elizabeth Adkins Czerepak, Chief Financial Officer
  • G. Kenneth Lloyd, Chief Scientific Officer
  • Ramon W. Mohanlal, Director, Chief Medical Officer, Executive VP-R&D

Who are some of BeyondSpring's key competitors?

What other stocks do shareholders of BeyondSpring own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeyondSpring investors own include Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Enterprise Products Partners (EPD), Johnson & Johnson (JNJ), Pfizer (PFE), Atara Biotherapeutics (ATRA), CorMedix (CRMD) and Dynavax Technologies (DVAX).

When did BeyondSpring IPO?

(BYSI) raised $4 million in an initial public offering (IPO) on Thursday, March 9th 2017. The company issued 200,000 shares at a price of $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) acted as the underwriter for the IPO.

What is BeyondSpring's stock symbol?

BeyondSpring trades on the NASDAQ under the ticker symbol "BYSI."

Who are BeyondSpring's major shareholders?

BeyondSpring's stock is owned by a number of retail and institutional investors. Top institutional investors include Alliancebernstein L.P. (7.69%), BlackRock Inc. (3.63%), Blair William & Co. IL (1.10%), State Street Corp (0.79%), Northern Trust Corp (0.56%) and Geode Capital Management LLC (0.51%).

Which institutional investors are selling BeyondSpring stock?

BYSI stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Marshall Wace LLP, Bank of America Corp DE, Nuveen Asset Management LLC, JPMorgan Chase & Co., Morgan Stanley, Morgan Stanley, and Diametric Capital LP.

Which institutional investors are buying BeyondSpring stock?

BYSI stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., BlackRock Inc., Blair William & Co. IL, Apis Capital Advisors LLC, Citadel Advisors LLC, Susquehanna International Group LLP, Parametric Portfolio Associates LLC, and Geode Capital Management LLC.

How do I buy shares of BeyondSpring?

Shares of BYSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BeyondSpring's stock price today?

One share of BYSI stock can currently be purchased for approximately $15.15.

How much money does BeyondSpring make?

BeyondSpring has a market capitalization of $592.46 million and generates $180,000.00 in revenue each year. The company earns $-60,970,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis.

How many employees does BeyondSpring have?

BeyondSpring employs 91 workers across the globe.

What is BeyondSpring's official website?

The official website for BeyondSpring is www.beyondspringpharma.com.

Where are BeyondSpring's headquarters?

BeyondSpring is headquartered at 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005.

How can I contact BeyondSpring?

BeyondSpring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at (646) 305-6387 or via email at [email protected].


This page was last updated on 9/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.